Drug Approval | September 28, 2024
FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Quinidine Sulphate helps manage rare irregular heartbeat conditions
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Subscribe To Our Newsletter & Stay Updated
